<DOC>
	<DOCNO>NCT00506415</DOCNO>
	<brief_summary>The purpose study support optimal use rivastigmine patch long-term treatment Alzheimer 's Disease patient demonstrate functional cognitive decline target maintenance dose rivastigmine patch 10 cm^2 .</brief_summary>
	<brief_title>Comparative Efficacy , Safety , Tolerability Rivastigmine 10 15 cm^2 Patch Patients With Alzheimer 's Disease ( AD ) Showing Cognitive Decline</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Male female patient 50 85 year age diagnosis probable Alzheimers Disease , Baseline MiniMental State Examination ( MMSE ) score 1024 inclusive , A primary caregiver willing accept responsibility supervise treatment , assess patient 's condition throughout study , provide input efficacy assessment . For double blind : Meet decline criterion functional ( assessed investigator ) cognitive ( assessed 1 point reduction MiniMental State Examination ) score visit 3 point reduction baseline ) decline week 23 , 36 48 . Presence advance , severe , progressive , unstable disease type could interfere efficacy safety assessment put patient particular risk , Any medical neurological condition Alzheimers Disease could explain patient 's dementia , A diagnosis probable possible vascular dementia , A current diagnosis unsuccessfullytreated depression , mental disorder may interfere evaluation patient 's response study medication , A history current diagnosis cerebrovascular disease ( e.g . stroke ) , A current diagnosis severe unstable cardiovascular disease ( e.g . unstable coronary artery disease ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>Patch</keyword>
	<keyword>Cognitive</keyword>
	<keyword>Decline</keyword>
</DOC>